Novartis Gleevec Will Cost Patients As Much As $30,000 Per Year
Executive Summary
Gleevec will cost between $2,000-$2,500 for a month of therapy, or up to $30,000 annually to treat chronic myeloid leukemia. The price is comparable to other chemotherapy and interferon therapies used in CML, Novartis Oncology President David Epstein maintained during a May 10 press conference.
You may also be interested in...
Gleevec Indigent Patient Program Will Continue After Medicare Rx
Novartis expects more than half of the patients currently receiving free doses of the oral oncologic Gleevec to qualify for the new Medicare prescription drug benefit in 2006
Gleevec Indigent Patient Program Will Continue After Medicare Rx
Novartis expects more than half of the patients currently receiving free doses of the oral oncologic Gleevec to qualify for the new Medicare prescription drug benefit in 2006
AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May
AstraZeneca is launching the lung cancer agent Iressa at a 25% discount to Novartis' chronic myelogenous leukemia therapy Gleevec